Sökning: "pharmaceutical reimbursement"

Visar resultat 1 - 5 av 7 uppsatser innehållade orden pharmaceutical reimbursement.

  1. 1. Paying the Piper : The Consequences of Including Generic Prices in Reimbursement Decisions for Prescription Pharmaceuticals

    Magister-uppsats, Linköpings universitet/Nationalekonomi; Linköpings universitet/Filosofiska fakulteten

    Författare :Anton Klockhoff; Wilmer Larsson; [2023]
    Nyckelord :pharmaceutical reimbursement; genericization; endogenous pricing; treatment displacement; cost-effectiveness analysis; R D incentives;

    Sammanfattning : Objectives: The Dental and Pharmaceutical Benefits Agency (TLV) is responsible for deciding which prescription pharmaceuticals should be subsidized in Sweden. Cost-effectiveness analyses are fundamental to its decision-making, but future price reductions following patent expiry are excluded from these analyses. LÄS MER

  3. 2. En miljöpremie i läkemedelsförmånssystemet : Lösningen på läkemedelsföretagens miljöförstöring?

    Kandidat-uppsats, Uppsala universitet/Nationalekonomiska institutionen

    Författare :Lisa Johansson; Alva Mickelsson; [2022]
    Nyckelord :Health economics; environmental bonus; generic pharmaceutical market; Bertrand competition; Hälsoekonomi; miljöpremie; generikamarknaden; Bertrandmodellen;

    Sammanfattning : In May 2021 the Swedish government decided to establish a trial period for an environmental bonus within the swedish reimbursement system, with the purpose to reduce the emissions of antibiotics and carbon dioxide from the pharmaceutical industry. This thesis examines the effect of the bonus on the pharmaceutical market and whether the goal set by the government can be met based on economic theory. LÄS MER

  4. 3. An Analysis of the Decision-making Process of the TLV and the Willingness to Pay for Healthcare in Sweden

    Master-uppsats, Göteborgs universitet/Graduate School

    Författare :Jens Dahlstrand; Fredrik Sandberg; [2016-10-03]
    Nyckelord :;

    Sammanfattning : The Dental and Pharmaceutical Benefits Agency (TLV) is the Swedish government agency who decides if a new medicine should be included in the benefit scheme or not. This study investigates which implicit factors influence the agency’s reimbursement decisions and how the TLV values different properties of a medicine. LÄS MER

  5. 4. Alternative legal incentives for antibiotic research and development : The role and function of legal mechanisms

    Uppsats för yrkesexamina på avancerad nivå, Uppsala universitet/Juridiska institutionen

    Författare :Anna Sundberg; [2016]
    Nyckelord :;

    Sammanfattning : In Europe there are 25 000 deaths per year as a result of antimicrobial resistance and in the world the estimated annual number of deaths is 700 000. By 2050, it has been predicted that 10 million people per year could die from being resistant to antibiotic compounds. LÄS MER

  7. 5. Companion Diagnostics Development and Commercialization : A Case Study from the Diagnostics’ Perspective

    Magister-uppsats, KTH/Hållbarhet och industriell dynamik

    Författare :Andreas Nolting; [2015]
    Nyckelord :Companion diagnostics; in-vitro; EME; FDA; Stratified medicine; Biomarker; Clinical utility; Medical Devices;

    Sammanfattning : The value proposition of Personalized Medicine is to deliver the “right drug, to the right patient, at the right time”. Companion diagnostics is the required tool for Personalized Medicine used to aid clinical decision making with the aim to identify patients who are most suitable for a given treatment approach and to avoid adverse effects. LÄS MER